Condition
NRG1 Fusion
Total Trials
4
Recruiting
0
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
25.0%
1 terminated out of 4 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
1 of 0 completed with results
Key Signals
1 with results0
Data Visualizations
Phase Distribution
2Total
P 2 (2)
Trial Status
Unknown1
Active Not Recruiting1
Enrolling By Invitation1
Terminated1
Clinical Trials (4)
Showing 4 of 4 trials
NCT07122882Enrolling By Invitation
Integrated Genomics in Oncogene-driven NSCLC With Acquired Resistance
NCT04100694UnknownPrimary
Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor
NCT02912949Phase 2Active Not Recruiting
A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)
NCT03805841Phase 2Terminated
Study of Tarloxotinib in Pts With NSCLC (EGFR Exon 20 Insertion, HER2-activating Mutations) & Other Solid Tumors With NRG1/ERBB Gene Fusions
Showing all 4 trials